Thorium dioxide-related haemangiosarcoma of the liver.
Rare tumours of the liver are occasionally seen; thorium dioxide-related haemangiosarcoma of the liver, with an estimated frequency of 0.14 to 0.25 per million in the normal population, is one of these. Causes, epidemiology and pathobiology are described related to a clinical case of angiosarcoma. A differentiation of hepatic tumours with imaging techniques is presented. Last, a short review on up-to-date treatment of haemangiosarcoma is discussed. Lessons can always be learned from history: will the contrast agent gadolinium be the Th232 of this era?
van Kampen
R J W
RJ
Department of Internal Medicine, Maasland Hospital, Sittard, the Netherlands. rjw.vankampen@gmail.com
Erdkamp
F L G
FL
Peters
F P J
FP
D000368:Aged; D003287:Contrast Media / Q000009:adverse effects; D006394:Hemangiosarcoma / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D009426:Netherlands / Q000453:epidemiology; D011379:Prognosis; D012307:Risk Factors; D013911:Thorium Dioxide / Q000009:adverse effects* / Q000494:pharmacology; D013997:Time Factors
D003287:Contrast Media; D013911:Thorium Dioxide